Login
$IONS
$28.02 +$0.01 (0.04%) After hours

$IONS 8-K/A SEC Filings

Filed On Filing
03 Nov 2025 8-K/A: Entry into a Material Definitive Agreement

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREAT...

28 Jun 2013 8-K/A: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

On October 15, 2008, Isis Pharmaceuticals, Inc. (“Isis”) and RBS Asset Finance, Inc. (“RBS”) originally entered into a Loan Agreement related to an equipment financing. On June 27, 2012 Isis and RBS amended the Loan Agreement to extend t...

28 Jun 2012 8-K/A: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

On October 15, 2008, Isis Pharmaceuticals, Inc. (“Isis”) and RBS Asset Finance, Inc. (“RBS”) originally entered into a Loan Agreement related to an equipment financing. On June 27, 2012 Isis and RBS amended the Loan Agreement to extend t...

20 Jun 2011 8-K/A: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

On October 15, 2008, Isis Pharmaceuticals, Inc. (“Isis”) and RBS Asset Finance, Inc. (“RBS”) originally entered into a Loan Agreement related to an equipment financing. On November 15, 2010 Isis and RBS amended the Loan Agreement to exte...

23 Jun 2010 8-K/A: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

On June 21, 2010, Isis Pharmaceuticals, Inc. (“Isis”) drew approximately $3.1 million in additional principal under its Loan Agreement with RBS Asset Finance, Inc. (“RBS”). Isis and RBS originally entered into a Loan Agreement related to...

02 Oct 2009 8-K/A: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

On October 15, 2008, Isis Pharmaceuticals, Inc. (“Isis”) and RBS Asset Finance, Inc. (“RBS”) entered into a Loan Agreement related to an equipment financing, and on September 30, 2009 Isis and RBS amended the Loan Agreement to increase t...

30 Mar 2009 8-K/A: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

On October 15, 2008, Isis Pharmaceuticals, Inc. (“Isis”) and RBS Asset Finance, Inc. (“RBS”) entered into a Loan Agreement (the “Loan Agreement”) related to an equipment financing. Under the Loan Agreement, Isis and its subsidiaries may ...

12 Jan 2009 8-K/A: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +1 more

On January 30, 2008, Isis Pharmaceuticals, Inc. (“Isis”) and its former subsidiary, Ibis Biosciences (“Ibis”), entered into a Strategic Alliance Master Agreement, a Call Option Agreement and an Investor Rights Agreement with Abbott Molec...

17 Dec 2008 8-K/A: Entry into a Material Definitive Agreement

CARLSBAD, Calif. and Abbott Park, Ill., December 17, 2008 - Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Abbott (NYSE: ABT) announced today that Abbott has exercised its option to purchase the remaining equity ownership in Ibis Bioscien...

06 Feb 2008 8-K/A: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

On January 7, 2008, Isis Pharmaceuticals, Inc. (“Isis”) and Genzyme Corporation (“Genzyme”) announced a major strategic alliance in which Genzyme will develop and commercialize mipomersen. Mipomersen, formerly ISIS 301012, is a lipid-low...

07 Dec 2007 8-K/A: Financial Statements and Exhibits

We consent to the incorporation by reference in the Registration Statements (Form S-3 Nos. 33-55790, 33-72124, 33-75068, 33-96138, 333-71911, 333-90811, 333-38844, 333-71116, 333-71176, 333-89066, 333-89626, 333-128156, 333-130639, 333-1...

02 Oct 2007 8-K/A: Entry into a Material Definitive Agreement

ISIS ANNOUNCES HSR APPROVAL AND CLOSURE OF ITS COLLABORATION WITH ORTHO-MCNEIL, INC.

13 Nov 2006 8-K/A: Other Events

November 13, 2006 ISIS 301012 Phase 2 Results and Program Overview

05 May 2005 8-K/A: Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities

CARLSBAD, CA, May 5, 2005 — Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), today announced its financial results for the quarter ended March 31, 2005. The Company’s proforma loss from operations was $17.1 million for the three months ended M...

01 Mar 2005 8-K/A: Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities

Carlsbad, CA, March 1, 2005 - Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), today announced its unaudited financial results for the year ended December 31, 2004. In line with its guidance, the Company’s proforma loss from operations was $85...

05 Oct 2001 8-K/A: Financial Statements and Exhibits

CERTIFICATE OF DESIGNATION OF THE SERIES B CONVERTIBLE PREFERRED STOCK (PAR VALUE $.001 PER SHARE) OF ISIS PHARMACEUTICALS, INC.

16 Jun 1999 8-K/A: Financial Statements and Exhibits

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

08 Jun 1999 8-K/A: Completion of Acquisition or Disposition of Assets

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support